CZ300129B6 - Enterálne podávaný doplnek k parenterální výžive nebo cástecné enterálne/orální výžive vážne nemocných, chronicky nemocných a podvyživených pacientu - Google Patents

Enterálne podávaný doplnek k parenterální výžive nebo cástecné enterálne/orální výžive vážne nemocných, chronicky nemocných a podvyživených pacientu Download PDF

Info

Publication number: CZ300129B6
Authority: CZ; Czechia
Prior art keywords: supplement; glutamine; patients; daily dose; vitamin
Prior art date: 2000-11-17

Application number

CZ20031337A

Other languages

Czech (cs)

English (en)

Other versions

CZ20031337A3 (cs

Inventor

Kessler@Barbara

Riedel@Angelika

Suchner@Ulrich

Original Assignee

Fresenius Kabi Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-17

Filing date

2001-11-14

Publication date

2009-02-18

2001-11-14 Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh

2003-09-17 Publication of CZ20031337A3 publication Critical patent/CZ20031337A3/cs

2009-02-18 Publication of CZ300129B6 publication Critical patent/CZ300129B6/cs

Links

239000013589 supplement Substances 0.000 title claims abstract description 85
208000017667 Chronic Disease Diseases 0.000 title claims abstract description 28
208000015380 nutritional deficiency disease Diseases 0.000 title claims abstract description 28
208000002720 Malnutrition Diseases 0.000 title abstract description 5
235000000824 malnutrition Nutrition 0.000 title abstract description 5
230000001071 malnutrition Effects 0.000 title abstract description 5
208000028399 Critical Illness Diseases 0.000 title abstract 2
235000016236 parenteral nutrition Nutrition 0.000 title description 14
235000021542 oral nutrition Nutrition 0.000 title description 10
230000036961 partial effect Effects 0.000 title description 9
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 60
239000002243 precursor Substances 0.000 claims abstract description 33
239000003963 antioxidant agent Substances 0.000 claims abstract description 24
230000007358 intestinal barrier function Effects 0.000 claims abstract description 22
210000005027 intestinal barrier Anatomy 0.000 claims abstract description 20
239000000126 substance Substances 0.000 claims abstract description 17
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 9
229930195729 fatty acid Natural products 0.000 claims abstract description 9
239000000194 fatty acid Substances 0.000 claims abstract description 9
150000004665 fatty acids Chemical class 0.000 claims abstract description 9
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 56
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 50
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 39
235000016709 nutrition Nutrition 0.000 claims description 33
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 29
239000000758 substrate Substances 0.000 claims description 27
230000035764 nutrition Effects 0.000 claims description 26
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 23
235000006708 antioxidants Nutrition 0.000 claims description 23
150000004666 short chain fatty acids Chemical class 0.000 claims description 23
235000016804 zinc Nutrition 0.000 claims description 22
239000011701 zinc Substances 0.000 claims description 22
229910052725 zinc Inorganic materials 0.000 claims description 22
239000002773 nucleotide Substances 0.000 claims description 21
125000003729 nucleotide group Chemical group 0.000 claims description 21
235000011649 selenium Nutrition 0.000 claims description 21
239000011669 selenium Substances 0.000 claims description 21
229910052711 selenium Inorganic materials 0.000 claims description 21
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 20
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 20
229930003268 Vitamin C Natural products 0.000 claims description 20
235000019154 vitamin C Nutrition 0.000 claims description 20
239000011718 vitamin C Substances 0.000 claims description 20
UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims description 19
239000004471 Glycine Substances 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 17
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 16
235000013734 beta-carotene Nutrition 0.000 claims description 16
239000011648 beta-carotene Substances 0.000 claims description 16
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 16
229960002747 betacarotene Drugs 0.000 claims description 16
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 16
239000003925 fat Substances 0.000 claims description 15
235000019197 fats Nutrition 0.000 claims description 15
229930003427 Vitamin E Natural products 0.000 claims description 14
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 14
230000000968 intestinal effect Effects 0.000 claims description 14
235000019165 vitamin E Nutrition 0.000 claims description 14
239000011709 vitamin E Substances 0.000 claims description 14
230000015572 biosynthetic process Effects 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 12
239000011651 chromium Substances 0.000 claims description 12
229910052804 chromium Inorganic materials 0.000 claims description 12
235000021391 short chain fatty acids Nutrition 0.000 claims description 12
229940046009 vitamin E Drugs 0.000 claims description 12
230000003078 antioxidant effect Effects 0.000 claims description 11
235000018102 proteins Nutrition 0.000 claims description 11
102000004169 proteins and genes Human genes 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
235000013619 trace mineral Nutrition 0.000 claims description 11
239000011573 trace mineral Substances 0.000 claims description 11
235000021323 fish oil Nutrition 0.000 claims description 10
235000020660 omega-3 fatty acid Nutrition 0.000 claims description 10
229920002774 Maltodextrin Polymers 0.000 claims description 9
235000001014 amino acid Nutrition 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
-1 p-carotene Chemical compound 0.000 claims description 8
229940088594 vitamin Drugs 0.000 claims description 8
229930003231 vitamin Natural products 0.000 claims description 8
235000013343 vitamin Nutrition 0.000 claims description 8
239000011782 vitamin Substances 0.000 claims description 8
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 7
235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 7
229960005135 eicosapentaenoic acid Drugs 0.000 claims description 7
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 7
239000003531 protein hydrolysate Substances 0.000 claims description 7
238000003786 synthesis reaction Methods 0.000 claims description 7
239000005913 Maltodextrin Substances 0.000 claims description 6
235000021466 carotenoid Nutrition 0.000 claims description 6
150000001747 carotenoids Chemical class 0.000 claims description 6
229940035034 maltodextrin Drugs 0.000 claims description 6
108090000765 processed proteins & peptides Proteins 0.000 claims description 6
108010016626 Dipeptides Proteins 0.000 claims description 5
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
108010024636 Glutathione Proteins 0.000 claims description 4
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
235000018417 cysteine Nutrition 0.000 claims description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
229960003180 glutathione Drugs 0.000 claims description 4
235000011187 glycerol Nutrition 0.000 claims description 4
150000004667 medium chain fatty acids Chemical class 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
206010033645 Pancreatitis Diseases 0.000 claims description 3
206010049416 Short-bowel syndrome Diseases 0.000 claims description 3
150000002308 glutamine derivatives Chemical class 0.000 claims description 3
229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
208000003265 stomatitis Diseases 0.000 claims description 3
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
206010033647 Pancreatitis acute Diseases 0.000 claims description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
238000012084 abdominal surgery Methods 0.000 claims description 2
201000003229 acute pancreatitis Diseases 0.000 claims description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
150000003862 amino acid derivatives Chemical class 0.000 claims description 2
229960003067 cystine Drugs 0.000 claims description 2
229960000304 folic acid Drugs 0.000 claims description 2
235000019152 folic acid Nutrition 0.000 claims description 2
239000011724 folic acid Substances 0.000 claims description 2
235000021317 phosphate Nutrition 0.000 claims description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
235000013824 polyphenols Nutrition 0.000 claims description 2
150000003365 short chain fatty acid esters Chemical class 0.000 claims description 2
238000011477 surgical intervention Methods 0.000 claims description 2
229960003080 taurine Drugs 0.000 claims description 2
235000004554 glutamine Nutrition 0.000 claims 14
239000000654 additive Substances 0.000 claims 3
230000000996 additive effect Effects 0.000 claims 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 2
241000720950 Gluta Species 0.000 claims 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
229930003270 Vitamin B Natural products 0.000 claims 1
150000001408 amides Chemical class 0.000 claims 1
125000002091 cationic group Chemical group 0.000 claims 1
235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
229940090949 docosahexaenoic acid Drugs 0.000 claims 1
229940013317 fish oils Drugs 0.000 claims 1
150000002309 glutamines Chemical class 0.000 claims 1
229930182817 methionine Natural products 0.000 claims 1
235000006109 methionine Nutrition 0.000 claims 1
229960004452 methionine Drugs 0.000 claims 1
239000002674 ointment Substances 0.000 claims 1
235000019156 vitamin B Nutrition 0.000 claims 1
239000011720 vitamin B Substances 0.000 claims 1
230000000694 effects Effects 0.000 description 22
230000006870 function Effects 0.000 description 17
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 14
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 10
241000382353 Pupa Species 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
230000004054 inflammatory process Effects 0.000 description 9
210000000936 intestine Anatomy 0.000 description 9
206010061218 Inflammation Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000001900 immune effect Effects 0.000 description 8
208000014674 injury Diseases 0.000 description 8
230000004060 metabolic process Effects 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
235000015097 nutrients Nutrition 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
230000006378 damage Effects 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
239000012528 membrane Substances 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
230000009467 reduction Effects 0.000 description 7
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
206010040047 Sepsis Diseases 0.000 description 5
235000010323 ascorbic acid Nutrition 0.000 description 5
239000011668 ascorbic acid Substances 0.000 description 5
229960005070 ascorbic acid Drugs 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
230000001925 catabolic effect Effects 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000006872 improvement Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
210000004347 intestinal mucosa Anatomy 0.000 description 5
150000003904 phospholipids Chemical class 0.000 description 5
230000035882 stress Effects 0.000 description 5
230000008733 trauma Effects 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
230000006820 DNA synthesis Effects 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
206010053159 Organ failure Diseases 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
230000007123 defense Effects 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
150000002066 eicosanoids Chemical class 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
230000036542 oxidative stress Effects 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
230000009278 visceral effect Effects 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
230000006819 RNA synthesis Effects 0.000 description 3
108010046377 Whey Proteins Proteins 0.000 description 3
102000007544 Whey Proteins Human genes 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
229940087168 alpha tocopherol Drugs 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000004087 circulation Effects 0.000 description 3
206010009887 colitis Diseases 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
239000008103 glucose Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
230000003859 lipid peroxidation Effects 0.000 description 3
150000004668 long chain fatty acids Chemical class 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
150000003230 pyrimidines Chemical class 0.000 description 3
239000002342 ribonucleoside Substances 0.000 description 3
150000005846 sugar alcohols Polymers 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229960000984 tocofersolan Drugs 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
230000005945 translocation Effects 0.000 description 3
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
235000004835 α-tocopherol Nutrition 0.000 description 3
239000002076 α-tocopherol Substances 0.000 description 3
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
206010028116 Mucosal inflammation Diseases 0.000 description 2
201000010927 Mucositis Diseases 0.000 description 2
102000015439 Phospholipases Human genes 0.000 description 2
108010064785 Phospholipases Proteins 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
229960002433 cysteine Drugs 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
210000001526 defensive cell Anatomy 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
230000029087 digestion Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
238000005265 energy consumption Methods 0.000 description 2
235000020776 essential amino acid Nutrition 0.000 description 2
239000003797 essential amino acid Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
230000031891 intestinal absorption Effects 0.000 description 2
230000031146 intracellular signal transduction Effects 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000010606 normalization Methods 0.000 description 2
235000020665 omega-6 fatty acid Nutrition 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
235000021122 unsaturated fatty acids Nutrition 0.000 description 2
150000004670 unsaturated fatty acids Chemical class 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
235000021119 whey protein Nutrition 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 1
HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
RXTBLQVXNIECFP-FXQIFTODSA-N Ala-Gln-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RXTBLQVXNIECFP-FXQIFTODSA-N 0.000 description 1
IFTVANMRTIHKML-WDSKDSINSA-N Ala-Gln-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O IFTVANMRTIHKML-WDSKDSINSA-N 0.000 description 1
WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 1
241000024188 Andala Species 0.000 description 1
208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
206010070545 Bacterial translocation Diseases 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
101100438971 Caenorhabditis elegans mat-1 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229910021555 Chromium Chloride Inorganic materials 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
235000002918 Fraxinus excelsior Nutrition 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
GZUKEVBTYNNUQF-WDSKDSINSA-N Gly-Ala-Gln Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GZUKEVBTYNNUQF-WDSKDSINSA-N 0.000 description 1
CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 1
BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
206010019708 Hepatic steatosis Diseases 0.000 description 1
101000957299 Homo sapiens Coronin-7 Proteins 0.000 description 1
101000800546 Homo sapiens Transcription factor 21 Proteins 0.000 description 1
206010058558 Hypoperfusion Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
150000008540 L-glutamines Chemical class 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
101100024019 Mus musculus Mosmo gene Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
NMZKLLJQNNTBRJ-OIXZZONUSA-N TXA3 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)C\C=C/CC)O[C@@H]2O[C@H]1C2 NMZKLLJQNNTBRJ-OIXZZONUSA-N 0.000 description 1
102100033121 Transcription factor 21 Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
206010047623 Vitamin C deficiency Diseases 0.000 description 1
239000005862 Whey Substances 0.000 description 1
206010048259 Zinc deficiency Diseases 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
AVMNFQHJOOYCAP-UHFFFAOYSA-N acetic acid;propanoic acid Chemical compound CC(O)=O.CCC(O)=O AVMNFQHJOOYCAP-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960001570 ademetionine Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
108010044940 alanylglutamine Proteins 0.000 description 1
230000004075 alteration Effects 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000002956 ash Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000007375 bacterial translocation Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000002213 calciumantagonistic effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000002884 effect on inflammation Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000001842 enterocyte Anatomy 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
230000005281 excited state Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
235000012055 fruits and vegetables Nutrition 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
108010010147 glycylglutamine Proteins 0.000 description 1
210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
210000003547 hepatic macrophage Anatomy 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
235000008212 improved nutritional status Nutrition 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
230000008944 intestinal immunity Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
BISQPGCQOHLHQK-HDNPQISLSA-N leukotriene B5 Chemical compound CC\C=C/C\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O BISQPGCQOHLHQK-HDNPQISLSA-N 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
239000011785 micronutrient Substances 0.000 description 1
235000013369 micronutrients Nutrition 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
235000021243 milk fat Nutrition 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000003843 mucus production Effects 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000003170 nutritional factors Nutrition 0.000 description 1
235000003715 nutritional status Nutrition 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
150000002927 oxygen compounds Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
235000021075 protein intake Nutrition 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000003331 prothrombotic effect Effects 0.000 description 1
230000006825 purine synthesis Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
208000010233 scurvy Diseases 0.000 description 1
150000003342 selenium Chemical class 0.000 description 1
229940091258 selenium supplement Drugs 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000002438 stress hormone Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Mycology (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CZ20031337A 2000-11-17 2001-11-14 Enterálne podávaný doplnek k parenterální výžive nebo cástecné enterálne/orální výžive vážne nemocných, chronicky nemocných a podvyživených pacientu CZ300129B6 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10057290A DE10057290B4 (de)	2000-11-17	2000-11-17	Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten

Publications (2)

Publication Number	Publication Date
CZ20031337A3 CZ20031337A3 (cs)	2003-09-17
CZ300129B6 true CZ300129B6 (cs)	2009-02-18

Family

ID=7663817

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ20031337A CZ300129B6 (cs)	2000-11-17	2001-11-14	Enterálne podávaný doplnek k parenterální výžive nebo cástecné enterálne/orální výžive vážne nemocných, chronicky nemocných a podvyživených pacientu

Country Status (28)

Country	Link
US (1)	US7947303B2 (fr)
EP (1)	EP1337236B1 (fr)
JP (1)	JP2004513912A (fr)
KR (2)	KR100861889B1 (fr)
CN (1)	CN1477950A (fr)
AT (1)	ATE272390T1 (fr)
AU (2)	AU2002224848B2 (fr)
BR (1)	BRPI0115451B1 (fr)
CA (1)	CA2429270C (fr)
CZ (1)	CZ300129B6 (fr)
DE (2)	DE10057290B4 (fr)
DK (1)	DK1337236T3 (fr)
EE (1)	EE05209B1 (fr)
ES (1)	ES2223015T3 (fr)
HR (1)	HRP20030395B1 (fr)
HU (1)	HU228351B1 (fr)
IL (2)	IL155840A0 (fr)
IS (1)	IS2377B (fr)
MX (1)	MXPA03004348A (fr)
NO (1)	NO333003B1 (fr)
NZ (1)	NZ525812A (fr)
PL (1)	PL202031B1 (fr)
PT (1)	PT1337236E (fr)
RU (1)	RU2295952C2 (fr)
SI (1)	SI1337236T1 (fr)
SK (1)	SK286199B6 (fr)
WO (1)	WO2002039978A1 (fr)
ZA (1)	ZA200303722B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10254584A1 (de) *	2002-11-22	2004-06-09	HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie	Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker
WO2005023274A1 (fr) *	2003-09-05	2005-03-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Utilisation de selenium hautement dose pour traiter et prevenir une maladie inflammatoire ainsi qu'un dysfonctionnement mitochondrial
AU2004273759A1 (en) *	2003-09-19	2005-03-31	N.V. Nutricia	Method and composition for preventing multiple organ dysfunction syndrome
DE10349585A1 (de)	2003-10-24	2005-06-16	Biosyn Arzneimittel Gmbh	Spurenelementzusammensetzung für die Ernährung
DE202004015931U1 (de) *	2004-10-13	2005-01-05	Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh	Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
US20050148669A1 (en) *	2004-10-21	2005-07-07	Daniel Amato	Amino acid esters as nutrient supplements and methods of use
JP2008519838A (ja) *	2004-11-09	2008-06-12	ヒルズ・ペット・ニュートリシャン・インコーポレーテッド	遺伝子調節のための酸化防止剤の使用
JP2008524123A (ja) *	2004-12-21	2008-07-10	クリティカルケアコネクションズインク	治療用栄養組成物又は組合せ、及びそれらの使用方法
AU2006240560B2 (en)	2005-04-27	2011-10-27	N.V. Nutricia	Nutrition with lipids and non-digestible saccharides
EP1719543A1 (fr) *	2005-05-04	2006-11-08	Asan Labs., Ltd.	Utilisation d'inhibiteurs d'histone deacetylase pour le traitement de problèmes gastro-intestinaux
WO2006127695A2 (fr) *	2005-05-23	2006-11-30	State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Conjugues d'acide ascorbique
AU2006301389B9 (en) *	2005-08-26	2011-05-12	Société des Produits Nestlé S.A.	Nutrition for obese patients
DE102005046237A1 (de) *	2005-09-28	2007-04-05	Südzucker Aktiengesellschaft Mannheim/Ochsenfurt	Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
WO2007058612A1 (fr) *	2005-11-15	2007-05-24	Entress Ab	Medicament a utiliser en rapport avec la deterioration de cartilage
CN101365350A (zh) *	2006-01-09	2009-02-11	雀巢技术公司	应激患者的治疗
CN101472612B (zh) *	2006-06-14	2011-06-08	纽崔西亚公司	包含甘氨酸和乳铁蛋白的抗炎组合物及其应用
MY148671A (en) *	2006-10-19	2013-05-31	Nestec Sa	Long-term enteral feed for maintenance
KR100774816B1 (ko) *	2006-11-21	2007-11-07	동부일렉트로닉스 주식회사	반도체 소자의 ｍｉｍ 커패시터 제조 방법 및 구조
WO2009038458A1 (fr) *	2007-09-17	2009-03-26	N.V. Nutricia	Formulation nutritionnelle riches en énergie
RU2010119238A (ru) *	2007-10-14	2011-11-27	Юниверсити Оф Флорида Рисерч Фаундейшн Инк. (Us)	Состав для улучшения функции желудочно-кишечного тракта
RU2354380C1 (ru) *	2007-11-16	2009-05-10	Государственное образовательное учреждение высшего профессионального образования "Омская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Росздрава"	Способ медикаментозной коррекции вазомоторной функции эндотелия у детей с сахарным диабетом 1 типа, не имеющих микроангиопатий
RU2394583C1 (ru) *	2008-12-01	2010-07-20	Марк Абович Малков	Средство для профилактики обменных нарушений
IT1396935B1 (it)	2009-11-26	2012-12-20	Solartium Entpr Ltd	Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
WO2011139621A1 (fr) *	2010-04-26	2011-11-10	Nestec S.A.	Compositions nutritives, et procédé pour sevrer de l'alimentation parentérale en vue du passage à l'alimentation par voie intestinale
JP2014510530A (ja) *	2011-03-31	2014-05-01	ネステクソシエテアノニム	アルギニンレベルを増加させる栄養組成物及びその使用方法
EP2705844B1 (fr)	2011-04-13	2019-05-22	Ajinomoto Co., Inc.	Composition nutritionnelle
US8183227B1 (en)	2011-07-07	2012-05-22	Chemo S. A. France	Compositions, kits and methods for nutrition supplementation
US8168611B1 (en)	2011-09-29	2012-05-01	Chemo S.A. France	Compositions, kits and methods for nutrition supplementation
EP2580967A1 (fr) *	2011-10-11	2013-04-17	Nestec S.A.	Accélération de récupération musculaire après une atrophie du muscle induite par l'immobilisation
US9849144B2 (en)	2013-09-16	2017-12-26	Healios Oncology Nutrition, LLC	Glutamine and trehalose compositions
KR101572606B1 (ko) *	2014-11-24	2015-11-27	강원대학교산학협력단	Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
BR112017026185A2 (pt)	2015-06-10	2018-08-14	Ajinomoto Kk	agente e método para melhorar um distúrbio gastrointestinal induzido por exercício.
ES2638195B1 (es) *	2016-04-18	2018-08-02	Bioiberica, S.A.	Composiciones para la piel
CN116779143A (zh)	2017-05-09	2023-09-19	巴克斯特国际公司	胃肠外营养诊断系统、设备和方法
CN108208177A (zh) *	2017-11-28	2018-06-29	上海交通大学医学院附属新华医院	含丁酸类化合物的组合物及其应用
PL423673A1 (pl) *	2017-12-01	2019-06-03	Lewandowska Agata	Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
US20230105336A1 (en) *	2020-02-12	2023-04-06	Dsm Ip Assets B.V.	Direct delivery of antioxidants to the gut
WO2021191469A1 (fr) *	2020-03-27	2021-09-30	Basf Se	Composition pour le traitement d'un dysfonctionnement gastro-intestinal et/ou de morbidités associées
US11666548B2 (en)	2020-06-05	2023-06-06	Baxter International Inc.	Parenteral nutrition formulation
WO2022031787A1 (fr) *	2020-08-04	2022-02-10	Temple University-Of The Commonwealth System Of Higher Education	Procédés et compositions pour traiter le syndrome de libération des cytokines
US20220160669A1 (en)	2020-11-24	2022-05-26	Baxter International Inc.	Parenteral nutrition formulation
DE202021102589U1 (de)	2020-12-15	2021-05-28	Marco Lautenschläger	Verzehrfertiges, abgefülltes Getränk auf Basis eines natürlichen Mineralwassers
US20250195547A1 (en) *	2022-04-19	2025-06-19	Vanderbilt University	Compositions and methods of treatment for congenital diarrheal disorder
WO2023215458A1 (fr) *	2022-05-06	2023-11-09	Ageless Sciences, Inc.	Compositions et procédés pour ralentir le vieillissement et prolonger la durée de vie
CN116920075B (zh) *	2023-09-15	2024-01-02	潍坊市人民医院(潍坊市公共卫生临床中心)	一种肠内营养液及其制备方法
CN120419671B (zh) *	2025-06-26	2025-10-10	成都桥然生物科技有限公司	一种儿童促生长双组分复合物配方及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994014458A1 (fr) *	1992-12-23	1994-07-07	Abbott Laboratories	Aliments a usage medical destines au soutien nutritionnel de nouveaux-nes/de bebes souffrant de maladies metaboliques
EP0705542A1 (fr) *	1994-09-21	1996-04-10	Sandoz Nutrition Ltd.	Composition diététique destinée à des adolescents
EP0756827A2 (fr) *	1995-08-03	1997-02-05	B. Braun Melsungen Ag	Préparation pour l'alimentation
EP0891719A1 (fr) *	1997-07-14	1999-01-20	N.V. Nutricia	Composition dietique contenant de la methionine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3698912A (en) *	1969-07-01	1972-10-17	Morton Norwich Products Inc	Process for making nutrient composition
DE3135849A1 (de) *	1981-09-10	1983-03-17	Dr. Schumacher GmbH & Co KG, 4600 Dortmund	Beschichtungsstoff fuer korrosionsschutzzwecke
US4446389A (en) *	1982-03-15	1984-05-01	Ampex Corporation	Quadrature tach decoder circuit
CA1285491C (fr) *	1985-09-12	1991-07-02	Robert J. Smith	Methode de traitement de troubles cataboliques
ES2007350A6 (es) *	1987-05-29	1989-06-16	Ganadera Union Ind Agro	Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
IL94549A (en) *	1989-06-02	1996-08-04	Brigham & Womens Hospital	A pharmaceutical preparation containing glutamine
AU645070B2 (en) *	1990-04-10	1994-01-06	Nb International Technologies	Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
SE9002732D0 (sv) *	1990-08-24	1990-08-24	Kabivitrum Ab	Product containing growth factor
JP2524551B2 (ja) *	1992-02-28	1996-08-14	雪印乳業株式会社	グルタミン含量の高いペプチド組成物、その製造方法及び経腸栄養剤
US5326569A (en) *	1992-12-23	1994-07-05	Abbott Laboratories	Medical foods for the nutritional support of child/adult metabolic diseases
JP4059532B2 (ja) *	1994-08-15	2008-03-12	森永乳業株式会社	腸内細菌の体内移行を阻止するペプチド混合物と、このペプチド混合物を含有する組成物
JP4011638B2 (ja) *	1994-12-27	2007-11-21	イーエヌ大塚製薬株式会社	経口経腸栄養組成物
US5569680A (en) *	1995-02-13	1996-10-29	Trustees Of The Univ. Of Penna	Method of treating inflammatory bowel disease with tributyrin
JPH09323979A (ja) *	1996-06-04	1997-12-16	Meiji Milk Prod Co Ltd	核酸を用いた免疫調節組成物
GB9701674D0 (en) *	1997-01-28	1997-03-19	Novartis Nutrition Ag	Use of organic compounds
US6124486A (en) *	1997-01-31	2000-09-26	Eastman Chemical Company	Process for making low calorie triglycerides having long and short fatty acid chains
JP2001514667A (ja) *	1997-03-17	2001-09-11	タム，ユンケー．	肝臓脂肪症の予防のための組成物
GB9709082D0 (en) *	1997-05-06	1997-06-25	Ciba Geigy Ag	Organic compositions
US5922766A (en) *	1997-07-02	1999-07-13	Acosta; Phyllis J. B.	Palatable elemental medical food
AU2186699A (en) *	1998-02-09	1999-08-23	Meiji Milk Products Co., Ltd.	Preventives and remedies for intestinal mucosal disorder
US6369252B1 (en) *	1998-02-26	2002-04-09	The University Of Georgia Research Foundation, Inc.	Structured lipids
JP2002524612A (ja) *	1998-09-11	2002-08-06	ダニスコカルターアメリカ，インコーポレーテッド	カロリーが低減された可塑性脂肪組成物
JP2000119180A (ja) *	1998-10-06	2000-04-25	Nisshin Flour Milling Co Ltd	経腸栄養剤
US7115297B2 (en) *	2000-02-22	2006-10-03	Suzanne Jaffe Stillman	Nutritionally fortified liquid composition with added value delivery systems/elements/additives

2000
- 2000-11-17 DE DE10057290A patent/DE10057290B4/de not_active Expired - Fee Related
2001
- 2001-11-14 CA CA002429270A patent/CA2429270C/fr not_active Expired - Fee Related
- 2001-11-14 EE EEP200300198A patent/EE05209B1/xx unknown
- 2001-11-14 AT AT01994656T patent/ATE272390T1/de active
- 2001-11-14 PT PT01994656T patent/PT1337236E/pt unknown
- 2001-11-14 SI SI200130195T patent/SI1337236T1/xx unknown
- 2001-11-14 ES ES01994656T patent/ES2223015T3/es not_active Expired - Lifetime
- 2001-11-14 EP EP01994656A patent/EP1337236B1/fr not_active Expired - Lifetime
- 2001-11-14 IL IL15584001A patent/IL155840A0/xx unknown
- 2001-11-14 AU AU2002224848A patent/AU2002224848B2/en not_active Ceased
- 2001-11-14 CZ CZ20031337A patent/CZ300129B6/cs not_active IP Right Cessation
- 2001-11-14 SK SK561-2003A patent/SK286199B6/sk not_active IP Right Cessation
- 2001-11-14 BR BRPI0115451A patent/BRPI0115451B1/pt not_active IP Right Cessation
- 2001-11-14 DK DK01994656T patent/DK1337236T3/da active
- 2001-11-14 NZ NZ525812A patent/NZ525812A/en not_active IP Right Cessation
- 2001-11-14 HR HR20030395A patent/HRP20030395B1/xx not_active IP Right Cessation
- 2001-11-14 CN CNA018200478A patent/CN1477950A/zh active Pending
- 2001-11-14 AU AU2484802A patent/AU2484802A/xx active Pending
- 2001-11-14 KR KR1020037006682A patent/KR100861889B1/ko not_active Expired - Fee Related
- 2001-11-14 US US10/432,915 patent/US7947303B2/en not_active Expired - Fee Related
- 2001-11-14 JP JP2002542353A patent/JP2004513912A/ja active Pending
- 2001-11-14 PL PL361634A patent/PL202031B1/pl unknown
- 2001-11-14 MX MXPA03004348A patent/MXPA03004348A/es active IP Right Grant
- 2001-11-14 HU HU0301386A patent/HU228351B1/hu not_active IP Right Cessation
- 2001-11-14 KR KR1020087017023A patent/KR20080069280A/ko not_active Ceased
- 2001-11-14 RU RU2003117716/15A patent/RU2295952C2/ru not_active IP Right Cessation
- 2001-11-14 WO PCT/EP2001/013163 patent/WO2002039978A1/fr not_active Ceased
- 2001-11-14 DE DE50103152T patent/DE50103152D1/de not_active Expired - Lifetime
2003
- 2003-05-11 IL IL155840A patent/IL155840A/en not_active IP Right Cessation
- 2003-05-13 NO NO20032160A patent/NO333003B1/no not_active IP Right Cessation
- 2003-05-14 ZA ZA200303722A patent/ZA200303722B/en unknown
- 2003-05-14 IS IS6815A patent/IS2377B/is unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994014458A1 (fr) *	1992-12-23	1994-07-07	Abbott Laboratories	Aliments a usage medical destines au soutien nutritionnel de nouveaux-nes/de bebes souffrant de maladies metaboliques
EP0705542A1 (fr) *	1994-09-21	1996-04-10	Sandoz Nutrition Ltd.	Composition diététique destinée à des adolescents
EP0756827A2 (fr) *	1995-08-03	1997-02-05	B. Braun Melsungen Ag	Préparation pour l'alimentation
EP0891719A1 (fr) *	1997-07-14	1999-01-20	N.V. Nutricia	Composition dietique contenant de la methionine

Also Published As

Publication number	Publication date
RU2295952C2 (ru)	2007-03-27
NO20032160L (no)	2003-07-14
US7947303B2 (en)	2011-05-24
ATE272390T1 (de)	2004-08-15
NO333003B1 (no)	2013-02-11
EP1337236A1 (fr)	2003-08-27
BR0115451A (pt)	2004-01-06
IL155840A (en)	2008-11-03
KR100861889B1 (ko)	2008-10-09
DE10057290B4 (de)	2004-01-08
HU228351B1 (hu)	2013-03-28
IS2377B (is)	2008-07-15
HUP0301386A3 (en)	2008-04-28
HRP20030395A2 (en)	2005-04-30
KR20030069172A (ko)	2003-08-25
ZA200303722B (en)	2004-04-16
SK5612003A3 (en)	2003-10-07
CA2429270A1 (fr)	2002-05-23
AU2484802A (en)	2002-05-27
DE50103152D1 (de)	2004-09-09
US20040097404A1 (en)	2004-05-20
SK286199B6 (sk)	2008-05-06
KR20080069280A (ko)	2008-07-25
PL361634A1 (en)	2004-10-04
NZ525812A (en)	2004-03-26
PL202031B1 (pl)	2009-05-29
DK1337236T3 (da)	2004-12-13
CN1477950A (zh)	2004-02-25
EP1337236B1 (fr)	2004-08-04
HRP20030395B1 (hr)	2011-10-31
MXPA03004348A (es)	2003-08-19
AU2002224848B2 (en)	2006-06-15
EE05209B1 (et)	2009-10-15
WO2002039978A1 (fr)	2002-05-23
CZ20031337A3 (cs)	2003-09-17
JP2004513912A (ja)	2004-05-13
CA2429270C (fr)	2009-08-18
BRPI0115451B1 (pt)	2016-07-19
NO20032160D0 (no)	2003-05-13
HUP0301386A2 (hu)	2003-09-29
PT1337236E (pt)	2004-11-30
SI1337236T1 (en)	2004-12-31
ES2223015T3 (es)	2005-02-16
WO2002039978A8 (fr)	2002-07-18
DE10057290A1 (de)	2002-06-06
IL155840A0 (en)	2003-12-23
IS6815A (is)	2003-05-14
EE200300198A (et)	2003-08-15

Publication	Publication Date	Title
CZ300129B6 (cs)	2009-02-18	Enterálne podávaný doplnek k parenterální výžive nebo cástecné enterálne/orální výžive vážne nemocných, chronicky nemocných a podvyživených pacientu
US9629386B2 (en)	2017-04-25	Nutrition composition
US5902829A (en)	1999-05-11	Method of modulating microcirculation
JP2013100336A (ja)	2013-05-23	癌患者に対する長期栄養供給
WO1988001861A1 (fr)	1988-03-24	Apport nutritionnel ou therapie pour personnes susceptibles de souffrir de maladies atherosclereuses, vasculaires, cardiovasculaires et/ou thrombotiques ou en traitement pour ces maladies
EP1437945A1 (fr)	2004-07-21	Utilisation de cystathionine
US6797729B1 (en)	2004-09-28	Therapeutic glutamine and N-actyl-cysteine composition
EP0655244B1 (fr)	2002-04-17	Composition à base d'acides aminés pour le traitement d'infections
Zhou et al.	2007	Immune-modulating enteral formulations: optimum components, appropriate patients, and controversial use of arginine in sepsis
HK1060696A (en)	2004-08-20	Supplement to be enterally administered for parenteral nutrition of partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition
Schütz et al.	1998	O. 42 Pathogenesis of malnutrition in patients with hepatocellular carcinoma (HCC)
Barber et al.	1998	0.43 A fish oil-enriched nutritional supplement reverses weight-loss in patients with advanced pancre-atic cancer
MXPA97006140A (en)	1998-07-03	Compositions of amino acids and the use of them in nutrition clin
MXPA97008873A (en)	1998-10-30	Method for modular microcirculac

Legal Events

Date	Code	Title	Description
2021-06-02	MM4A	Patent lapsed due to non-payment of fee	Effective date: 20201114